Genmab A/S (CPH:GEN) Has Attractive Fundamentals

As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health to their future outlook. In the case of Genmab A/S (CPH:GEN), it is a company with great financial health as well as a a strong track record of performance. In the following section, I expand a bit more on these key aspects. For those interested in digger a bit deeper into my commentary, read the full report on Genmab here.

Flawless balance sheet with proven track record

GEN has a strong track record of performance. In the previous year, GEN delivered an impressive double-digit return of 17% Unsurprisingly, GEN surpassed the industry return of 13%, which gives us more confidence of the company’s capacity to drive earnings going forward. GEN’s ability to maintain an adequate level of cash to meet upcoming liabilities is a good sign for its financial health. This indicates that GEN has sufficient cash flows and proper cash management in place, which is a crucial insight into the health of the company. GEN currently has no debt on its balance sheet. This implies that the company is running its operations purely on off equity funding. which is rather impressive for a ø71b market cap company. Therefore the company has plenty of headroom to grow, and the ability to raise debt should it need to in the future.

CPSE:GEN Income Statement, March 4th 2019
CPSE:GEN Income Statement, March 4th 2019

Next Steps:

For Genmab, I’ve compiled three pertinent factors you should further research:

  1. Future Outlook: What are well-informed industry analysts predicting for GEN’s future growth? Take a look at our free research report of analyst consensus for GEN’s outlook.
  2. Valuation: What is GEN worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether GEN is currently mispriced by the market.
  3. Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of GEN? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.